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deficiency of folate is connected with a variety of human diseases, such
as atherosclerosis, neural tube defects, and cancer. Epidemiological studies
have shown an inverse relationship between folate status and the risks of
some malignancies including cancer of colon, esophagus, stomach, pancreas,
lung, cervix, ovary, breast and leukemia. However, the molecular mechanism
underlying of FA-induced anti-cancer activity is not fully understood. The aim
of this study was to use human colon adenocarcinoma cell line COLO-205
to address this issue. Our results show that FA inhibits the growth COLO-
205 through proliferation inhibition. FA-induced cell cycle arrest in COLO-205
cells occurred when the cyclin-CDK system was inhibited just as p21 and p27
protein levels increased. In vivo study demonstrates that daily i.p. injection with
folic acid significantly reduced the tumor volume and prolonged the life span in
the COLO-205 tumor-bearing null mice. The findings from the present in vitro
and in vivo studies suggest the potential applications of FA in treating human
colon cancers.
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Introduction: Bladder cancer is a common malignancy worldwide. Treatment
typically involves surgery and chemotherapy, but outcomes remain far from
optimal. Research is now focused on the identification of molecular targets
which could be used for targeted therapy. The epidermal growth factor
receptors 1 and 2 (EGFR and HER2) have been found to be overexpressed
in some bladder cancers and have been linked to poor prognosis. These
cell membrane receptors have tyrosine kinase activity and transduce signals
controlling cell growth, survival and differentiation through various intracellular
pathways. EGFR and HER2 are deregulated in various cancers, but their role
in bladder cancer is still undefined. We aimed to investigate whether targeted
drugs against EGFR and HER2 could be effective treatments for bladder
cancer. These studies could provide the rationale for the use of novel targeted
therapies in bladder cancer.
Material and Method: We have used six bladder cancer cell lines and three
tyrosine kinase inhibitors (TKI) to inhibit EGFR and/or HER2; lapatinib, a dual
inhibitor of EGFR and HER2, erlotinib, which specifically inhibits EGFR, and
CP654577, a novel compound that inhibits HER2. Effect of the TKIs on cell
proliferation, cell cycle and apoptosis on the bladder cancer cell lines has been
analysed.
Results and Discussion: Cell proliferation of the six bladder cancer cell lines
was analysed after being treated with the TKIs, obtaining variable sensitivities
among the cell lines. Relative expression of EGFR and HER2 in the six bladder
cancer cell lines was studied by western blot and a significant correlation
between erlotinib sensitivity and EGFR expression was found. Cell cycle
analysis after all three TKI treatments showed an increase in G0/G1 phase.
A significant increase in dead cells due to apoptosis could also be seen after
lapatinib and CP654577 treatment, but no apoptosis was induced after erlotinib
treatment. These results suggest that inhibiting HER2 induces apoptosis on
these cells, but this effect is not seen after EGFR inhibition. We are currently
investigating this by analysing some apoptosis markers in these cells.
Conclusion: These results support the hypothesis that EGFR expression
could be a predictive marker for sensitivity to treatments targeted at this
receptor and could identify bladder cancer patients suitable for this therapy.
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ZEB1 is one of the drivers of EMT (Epithelial Mesenchymal Transition) that,
by repressing E-cadherin and cell polarity genes, has a crucial role in tumor
progression and metastasis.
In this study we investigated the role of ZEB1 in basal-like/triple negative breast
cancer, a particularly aggressive subtype of breast cancer (BC) characterized
by the lack of hormone receptors and HER2. Furthermore, this subtype of BC
frequently expresses EGF receptor (EGFR) and is enriched with EM-transited
cells showing features of cancer stem cells (CSC).
Loss of function studies in two breast cell models, MDAMB231 and
MDAMB157, whose features resemble those of highly aggressive EMT
transited BC, showed that actually the down-regulation of ZEB1 reduced
the CD44+/CD24− stem population, induced a luminal ’differentiation’
as demonstrated by the augment of EpCAM expression, and partially
reverted the EMT phenotype. Interestingly, a marked transition towards the
epithelial phenotype was achieved by the simultaneous ZEB1 silencing and
demethylating treatment. In fact, E-cadherin expression, a hallmark of epithelial
cells, was noticeably induced in ZEB1 depleted cells by a demethylating
treatment that concurrently stimulated the expression of miR200c, a regulator
of several EMT-drivers. However, in these cell models we did not observe a
clear contribution of miR200c in the shrinkage of stem population induced by
ZEB1 downregulation.
Intriguingly, knock-down of ZEB1 promoted the activation of EGFR even in the
absence of stimuli and associated with an increased sensitivity to the EGFR
inhibitor 324674 in the MDAMB231 cell line.
Taken together these data suggest that the depletion of ZEB1 is not
sufficient to revert the EMT phenotype in highly metastatic models. Indeed,
concurrently demethylation was fundamental for a marked reversion of
mesenchymal phenotype. Importantly, ZEB1 expression and EMT might affect
response to EGFR-inhibitors in breast cancers prompting the needs for a
better characterization of EMT features in patients receiving EGFR targeting
therapies.
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Background: Stress-induced monoubiquitination of p53 is a crucial event for
the nuclear-cytoplasm-mitochondria trafficking and transcription-independent
pro-apoptotic functions of p53. Although an intact ubiquitination pathway and a
functional Nuclear Export Sequence (NES) are required for p53 nuclear export,
the role of specific residues within this region in regulating both processes
remains largely unknown.
Materials and Methods: Here we characterize the mechanisms accounting for
the nuclear accumulation of a new point mutation (Lys 351 to Asn) in the NES
of p53 identified in a cisplatin-resistant ovarian carcinoma cell line (A2780
CIS). In particular we evaluated the ubiquitination stauts of p53 K351N, its
tanslocation to mitochondria and mitochondria-dependent apoptosis.
Results: We found that K351N substitution abrogates the monoubiquitination
of p53 induced by both Mdm2 and MSL2 E3-ligases. As a consequence,
cells expressing p53 K351N mutant showed defects in cisplatin-induced
translocation of p53 to mitochondria, Bax oligomerization and mitochondrial
membrane depolarization.
Conclusion: These data identify K351N as a critical mutation of p53 that
contributes to the development and maintenance of resistance to cisplatin.
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Background: Docetaxel-based chemotherapy has generally been considered
as one of the effective treatments for prostate cancer. Unfortunately, clinical
treatment with docetaxel often encounters a number of undesirable side
effects, including drug resistance. Therefore, it has become essential to identify
molecular events that may be associated with the development of docetaxel
resistance. Tubulin isoforms have been previously examined for their resistant
ability to docetaxel in many cancers, but their real mechanisms remained
unclear. In this study, we evaluated the feasibility of employing docetaxel as
a cytotoxic agent for PC3 cells and to examine the role of acetyl-tubulin in
docetaxel-resistant prostate cancer.
Materials and Methods: A series of docetaxel-resistant PC3/DX cell
subclones, were established by chronically exposing PC3 to progressively
increased concentrations of docetaxel. Herein, we characterized the docetaxel-
mediated cytoxicity and molecular events in PC3 and PC3/DX cells by MTT
assay, Western blotting, RT-PCR and real-time PCR.
Results: Our results showed that levels of acetyl-tubulin, a-tubulin, b-tubulin,
g-tubulin and bIII-tubulin were significantly higher expression in PC3/DX than in
parental PC3 cells by Western blotting analysis. PC/DX with greater resistance
to docetaxel had higher levels of acetyl-tubulin than in PC3 cells. The
expression of acetyl-tubulin was gradually increased by docetaxel in a dose-
and time-dependent manner in PC3 cells. Histone deacetylase 6, a deacetyl
enzyme of tubulin, mRNA and protein levels were significantly decreased in
PC3/DX than in PC3 cells. Interestingly, we also found an evident up-regulation
of acetyl-tubulin protein expression after recombinant epidermal growth factor
treatment in a time-dependent manner in PC3 cells.
Conclusions: Up-regulation of acetyl-tubulin may play an important
chemoresistant role in docetaxel-resistant prostate cancer.
